ReviewCore evidence2013

Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis.

Tobias Engel Ayer Botrel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.